EA201300205A1 - METHOD FOR ACCELERATING THE GROWTH OF BACTERIAL BIOMASS AND THE SUPPRESSION OF VIRULENCE BACTERIA - Google Patents

METHOD FOR ACCELERATING THE GROWTH OF BACTERIAL BIOMASS AND THE SUPPRESSION OF VIRULENCE BACTERIA

Info

Publication number
EA201300205A1
EA201300205A1 EA201300205A EA201300205A EA201300205A1 EA 201300205 A1 EA201300205 A1 EA 201300205A1 EA 201300205 A EA201300205 A EA 201300205A EA 201300205 A EA201300205 A EA 201300205A EA 201300205 A1 EA201300205 A1 EA 201300205A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microorganisms
growth
activators
virulence
humans
Prior art date
Application number
EA201300205A
Other languages
Russian (ru)
Other versions
EA025623B1 (en
Inventor
Артур Викторович МАРТЫНОВ
Борис Славинович ФАРБЕР
Софья Борисовна ФАРБЕР
Original Assignee
Борис Славинович ФАРБЕР
Софья Борисовна ФАРБЕР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Борис Славинович ФАРБЕР, Софья Борисовна ФАРБЕР filed Critical Борис Славинович ФАРБЕР
Publication of EA201300205A1 publication Critical patent/EA201300205A1/en
Publication of EA025623B1 publication Critical patent/EA025623B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Изобретение относится к медицине, а именно к фармации, инфектологии и биотехнологии, и предназначено для лечения инфекционных заболеваний человека и животных путем подавления вирулентности бактерий, а также в биотехнологии для усиления наращивания биомассы микроорганизмов в производстве пробиотиков, молочнокислых заквасок, вакцинном производстве, спиртовом и дрожжевом производствах. В основу изобретения поставлена задача разработать активаторы роста микроорганизмов, не содержащие тяжелых металлов, нетоксичные для человека и животных, не обладающие мутагенным и канцерогенным действием и увеличивающие прирост количества микробных клеток в 2 и более раз, обладающие способностью также подавлять вирулентность микроорганизмов с возможностью использования этого свойства в лечении инфекционных заболеваний у людей и животных путём применения энхансеров перед курсом противомикробной терапии. Поставленная задача решается путем добавления в питательную среду для культивирования микроорганизмов смеси активаторов роста микроорганизмов группы индукторов накопления циклического аденозинмонофосфата с доказанной безвредностью для человеческого организма, что приводит к ускорению появления первых колоний и увеличению прироста количества микробных клеток в 2-4 раза, эти же активаторы могут применяться в лечении инфекционных заболеваний в качестве ингибиторов вирулентности микроорганизмов перед применением курса антимикробной терапии или вместе с ним. Причем в качестве активаторов роста микроорганизмов используют активаторы накопления циклического аденозинмонофосфата, такие как папаверин, бендазол иThe invention relates to medicine, namely to pharmacy, infectology and biotechnology, and is intended for the treatment of infectious diseases of humans and animals by suppressing the virulence of bacteria, and also in biotechnology to enhance the growth of biomass of microorganisms in the production of probiotics, lactic acid starter cultures, vaccine production, alcohol and yeast productions. The basis of the invention is the task to develop activators of the growth of microorganisms that do not contain heavy metals, non-toxic to humans and animals, do not have a mutagenic and carcinogenic effect and increase the growth in the number of microbial cells by 2 or more times, with the ability to also suppress the virulence of microorganisms with the possibility of using this property in the treatment of infectious diseases in humans and animals by the use of enhancers before a course of antimicrobial therapy. The problem is solved by adding to the nutrient medium for the cultivation of microorganisms a mixture of microorganism growth activators of the group of inducers of accumulation of cyclic adenosine monophosphate with proven harmlessness to the human body, which leads to an acceleration of the appearance of the first colonies and an increase in the number of microbial cells by 2-4 times, the same activators can used in the treatment of infectious diseases as inhibitors of virulence of microorganisms before applying the antimicrobial course th therapy or with it. Moreover, activators of the accumulation of cyclic adenosine monophosphate, such as papaverine, bendazole and

EA201300205A 2011-12-28 2011-12-28 Method for accelerating bacterial biomass growth and attenuating the virulence of bacteria EA025623B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2011/001060 WO2013100792A1 (en) 2011-12-28 2011-12-28 Method for accelerating bacterial biomass growth and attenuating the virulence of bacteria

Publications (2)

Publication Number Publication Date
EA201300205A1 true EA201300205A1 (en) 2014-11-28
EA025623B1 EA025623B1 (en) 2017-01-30

Family

ID=48698084

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300205A EA025623B1 (en) 2011-12-28 2011-12-28 Method for accelerating bacterial biomass growth and attenuating the virulence of bacteria

Country Status (3)

Country Link
EA (1) EA025623B1 (en)
IN (1) IN2014MN01483A (en)
WO (1) WO2013100792A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090763A1 (en) 2017-11-15 2020-08-03 Борис Славинович ФАРБЕР PHARMACEUTICAL COMPOSITION FOR STIMULATION OF STEM CELL DIVISION AND SUPPRESSION OF BACTERIA VIRULENCE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005340A1 (en) * 2005-06-15 2009-01-01 Medimush A/S Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell
WO2010055495A2 (en) * 2008-11-17 2010-05-20 Designer Energy Ltd. Methods and compositions for enhanced bacterial hydrolysis of cellulosic feedstocks

Also Published As

Publication number Publication date
EA025623B1 (en) 2017-01-30
IN2014MN01483A (en) 2015-04-17
WO2013100792A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
Natrah et al. The impact of quorum sensing on the virulence of Aeromonas hydrophila and Aeromonas salmonicida towards burbot (Lota lota L.) larvae
BR112014031658A2 (en) Mixotrophic method of aquaculture
IN2014DN06610A (en)
BR112012017831B8 (en) microbial oil, animal food and biomass comprising said microbial oil
EA201490512A1 (en) COMPOSITIONS CONTAINING CULTIVATED IN ANAEROBIC CONDITIONS HUMAN INTESTINE MICROBIOT
MX2014014690A (en) Microbial fermentation methods and compositions.
DE602007005233D1 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
BR112015006568A2 (en) lactic acid bacteria and compositions
IN2014DN09956A (en)
MY160740A (en) Method of producing lauric acid-containing oil or fat
EA201890407A1 (en) BACTERIA LACTOBACILLUS FERMENTUM REDUCING THE CONCENTRATION OF ACETALDEHYDE
NZ591874A (en) Photosynthetic microorganisms enriched in selenium using selenohydroxy acid compounds, uses thereof in nutrition, cosmetics and pharmacy
Mahdhi et al. Survival and retention of the probiotic properties of Bacillus sp. strains under marine stress starvation conditions and their potential use as a probiotic in Artemia culture
CN105624052A (en) Composite biological preparation used for efficient culture of aquatic products
EA201300205A1 (en) METHOD FOR ACCELERATING THE GROWTH OF BACTERIAL BIOMASS AND THE SUPPRESSION OF VIRULENCE BACTERIA
RU2562590C1 (en) METHOD FOR ENHANCING ANTIBIOTIC SUSCEPTIBILITY OF OPPORTUNISTIC-PATHOGENIC MICROFLORA BY ADDING LACTIC ACID FEED SUPPLEMENT CONTAINING CULTURE Bifidobacter longum "Б-41" in vitro
MX2015017262A (en) Highly siderophore-producing bacterial mixture, production method thereof and use of same as a phytopathogen inhibitor.
MY196871A (en) Composition which contains lactic acid bacterium as effective component and which is for preventing or ameliorating skin condition deterioration caused by abnormal proliferation of specific bacterium in skin
RU2501851C1 (en) Bacillus licheniformis STRAIN HAVING APPARENT ANTAGONISM IN RELATION TO Salmonella typhi, Staphyloccus aureus, Listeria monocytogenes AND RESISTANCE TO STREPTOMYCIN AND NALIDIXIC ACID
SG11202108657YA (en) Method for producing culture of lactic acid bacterium and/or bacterium belonging to genus bifidobacterium
CN105176887A (en) Method for culturing escherichia coli
Goren et al. The microbiome in hair disorders
Pintado et al. Manipulating Ulva-associated bacterial communities: a possible strategy for bacterial control in IMTA-RAS cultures?
RU2014116492A (en) BIOLOGICAL PRODUCT - ACTIVATOR OF BIO-DISTRACTION OF ORGANIC WASTE ANIMAL AND POULTRY FOOD, CONSORTIUM OF MICRO-ORGANISM STRAINS USED FOR OBTAINING A BIOLOGICAL PRODUCT, AND A METHOD FOR ITS
Mokrozub et al. Antistaphylococcal action of lacto-and bifidobacteria and interleukin-2

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KG MD TJ TM